Ramipril 87333-19-5
Ramipril (marketed by Sanofi-Aventis as Tritace and by King Pharmaceuticals as Altace) is an angiotensin-converting enzyme (ACE) inhibitor, used to treat hypertension and congestive heart failure. ACE inhibitors lower the production of angiotensin II, therefore relaxing arterial muscles while at the same time enlarging the arteries, allowing the heart to pump blood more easily, and increasing blood flow due to more blood being pumped into and through larger passageways.
| Systematic (IUPAC) name: |
(2S,3aS,6aS)-1-[(2S)-2-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylicacid |
| Ramipril CAS number: |
87333-19-5 |
| ATC code: |
C09AA05 |
| PubChem: |
5362129 |
| DrugBank: |
APRD00009 |
| Formula: |
C23H32N2O5 |
| Molecular mass: |
416.511 g/mol |
| Ramipril Assay/Purity: |
Typically NLT 98% |
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
